Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Michaela Liedtke,1 Clare J. Twist,2 Bruno C. Medeiros,1 Jason R. Gotlib,1 Caroline Berube,1 Marcia M. Bieber,3 Neelima M. Bhat,3 Nelson N. Teng,3 and Steven E. Coutre1

1Departments of Medicine, 2Pediatrics and 3Gynecology, Stanford University School of Medicine, Stanford, CA, USA


Online Supplementary Figure S1. Scanning electron microscopy image of B-cell ALL blasts treated with mAb216. Cells were incubated with 10 μg/mL of mAb216 for 15 min at 4 °C, washed three times with PBS and fixed with 2% glutaraldehyde and post fixed in 1% OsO4, dehydrated in 30-100% ethanol and dried in hexamethyldisilazane. The cells were mounted onto a double sticky Pelco carbon conductive stub and gold coated on a Polaron 5300. The cells were examined by Philips 505 scanning electron microscope (Philips, Einhoven, Holland) and images recorded on film. The print was scanned into jpeg.